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by Streptomyces formicae isolated from African
Tetraponera plant-ants†
Zhiwei Qin,a John T. Munnoch,b Rebecca Devine,b Neil A. Holmes,b Ryan F. Seipke,c
Karl A. Wilkinson,d Barrie Wilkinson*a and Matthew I. Hutchings*b
We report a new Streptomyces species named S. formicae that was isolated from the African fungus-
growing plant-ant Tetraponera penzigi and show that it produces novel pentacyclic polyketides that are
active against MRSA and VRE. The chemical scaﬀold of these compounds, which we have called the
formicamycins, is similar to the fasamycins identiﬁed from the heterologous expression of clones
isolated from environmental DNA, but has signiﬁcant diﬀerences that allow the scaﬀold to be decorated
with up to four halogen atoms. We report the structures and bioactivities of 16 new molecules and
show, using CRISPR/Cas9 genome editing, that biosynthesis of these compounds is encoded by a single
type 2 polyketide synthase biosynthetic gene cluster in the S. formicae genome. Our work has identiﬁed
the ﬁrst antibiotic from the Tetraponera system and highlights the beneﬁts of exploring unusual
ecological niches for new actinomycete strains and novel natural products.Introduction
Over half of the antibiotics in clinical use are derived from the
natural products (secondary metabolites) of Streptomyces
bacteria and their close relatives, and most of these were
introduced into the clinic during a ‘golden age’ of antibiotic
discovery between 1940 and 1960.1 The misuse of antibiotics
over the last 50 years has led to an alarming rise in antimicro-
bial resistance (AMR) which is arguably the greatest medical
challenge humans will face this century. Recently, however, the
advent of facile, large-scale genome sequencing and the
discovery of new antibiotic-producing strains in under-explored
environments has reinvigorated the eld of natural products
discovery. The wealth of genomic data now available has
demonstrated that Streptomyces and other lamentous actino-
mycetes have the capacity to produce many more natural
products than are identied aer culturing in the laboratory:
typically only 10–25% of their identiable biosynthetic gene
clusters (BGCs) are expressed under standard laboratory
conditions and new classes of BGC remain to be discovered.2,3n Innes Centre, Norwich Research Park,
inson@jic.ac.uk
of East Anglia, Norwich Research Park,
@uea.ac.uk
Astbury Centre for Structural Molecular
, UK
rtment of Chemistry, University of Cape
Africa
(ESI) available: General remarks; full
1 and S2. See DOI: 10.1039/c6sc04265a
Chemistry 2017We have been exploring the chemical ecology of protective
mutualisms formed between actinomycete bacteria and fungus-
growing insects in order to understand how these associations
are formed and to explore this niche as a potential source of new
antibiotics.4 In addition to the fungus-growing attine ants of
South and Central America, which use actinomycete-derived
antibiotics in their fungi-culture,5,6 it was recently discovered
that many plant-ants also cultivate fungi.7–9 Plant-ants live in
a mutualism with their host plant and provide protection from
larger herbivores. In return, the host plants have evolved spe-
cialised hollow structures called domatia that house and protect
the ants.10 South American Allomerus plant-ants and African
Tetraponera plant-ants both grow fungi inside their domatia
and they are associated with antibiotic-producing actinomycete
bacteria.11,12
We previously reported the isolation of lamentous actino-
mycete bacteria, including Streptomyces and Saccharopolyspora
strains, from the domatia and worker ants of Tetraponera pen-
zigi plant-ants collected in Kenya.12 Genome sequencing of
these strains allowed us to identify new species with genomes
encoding novel and/or atypically large numbers of BGCs based
on antiSMASH analysis.13 We consider strains containing
signicantly higher numbers of BGCs than typical strains (for
Streptomyces sp. this is in the range 30–35) to be ‘talented’ with
respect to their potential for yielding new natural products. One
such organism, which we designate Streptomyces formicae KY5,
also displayed a unique antagonistic activity against pathogenic
drug resistant bacteria and fungi, including methicillin resis-
tant Staphylococcus aureus (MRSA) and the multidrug resistant
fungal pathogen Lomentospora prolicans.14 SubsequentChem. Sci.
Chemical Science Edge Article
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View Article Onlinebioassay guided fractionation using the sensitive test strain
Bacillus subtilis led to the isolation and structural elucidation of
thirteen new polyketide natural products that share a rare
pentacyclic structure, some of which contain up to four chlorine
atoms. These compounds fall into two groups. The rst group
(1–3) have an aromatic C-ring structure with sp2 carbon atoms
at C10/C19, and lack any formal chiral centres. We have named
these compounds fasamycin C–E respectively given their very
close structural similarity to fasamycins A and B described
previously from heterologous expression of a clone expressing
a type 2 polyketide synthase (PKS) BGC isolated from an envi-
ronmental DNA derived library.15 In contrast, compounds 4–13
are highly modied compared to the fasamycins with a non-
aromatic C-ring and chiral centres at C10 and C19. We have
named this group of compounds the formicamycins because
they are the rst natural products to be characterised from S.
formicae and are structurally and biosynthetically distinct from
the fasamycins (see below). Supplementation of the growth
medium with sodium bromide resulted in the incorporation of
bromine to yield three additional formicamycin congeners
(14–16).
The formicamycins and fasamycins are active against clin-
ical isolates of MRSA and vancomycin resistant enterococci
(VRE), but do not display Gram-negative antibacterial or anti-
fungal activity. The availability of sixteen congeners allowedFig. 1 Structures of the previously reported fasamycins A & B, the new
Chem. Sci.their structure–activity relationship (SAR) to be examined. We
then grew MRSA for 20 generations in the presence of sub-
inhibitory concentrations of three formicamycins and re-
determined the MICs for MRSA. These assays showed that
MRSA does not easily acquire spontaneous resistance to for-
micamycins, at least under the conditions tested. Finally, we
show, using CRISPR/Cas9 genome editing, that biosynthesis of
these compounds is encoded by a type 2 PKS BGC in the S.
formicae chromosome, and that re-introduction of this BGC
restores biosynthesis of formicamycins in S. formicae. Identi-
cation of the formicamycin BGC allowed us to propose a plau-
sible biosynthetic pathway. Deletion of forV encoding a putative
avin dependent halogenase abolished the production of any
halogenated molecules and stalled the biosynthetic pathway at
the fasamycin congener stage (1–3) indicating halogenation is
a critical step required for further post-PKS modication to
yield the formicamycin scaﬀold.Results and discussion
Discovery of Streptomyces formicae: a talented new species
We previously isolated a number of lamentous actinomycete
strains from the domatia and worker ants of the African Tetra-
ponera penzigi-Acacia plant-ant mutualism.12 On the basis of 16S
rDNA sequencing and morphological characteristics we chosefasamycin congeners C–E (1–3) and the formicamycins A–M (4–16).
This journal is © The Royal Society of Chemistry 2017
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View Article Onlinesix individual strains for genome sequencing using the Pacic
Biosciences RSII platform with assembly using the HGAP2
pipeline. The resulting high-quality assemblies were analysed
using the genome mining platform antiSMASH 3.0.13 One
isolate in particular caught our attention as its genome
harbours at least 39 BGCs and extracts derived from growth on
agar plates showed promising bioactivities in anti-infective
assays against B. subtilis and the fungal pathogens Candida
albicans CA6 16 and Lomentospora prolicans CBS116904 (see
below). These results prompted us to examine the relative
genetic relationship with sequenced streptomycetes, for which
there are now more than 950 complete and dra genome
sequences available (ESI Fig. S1†). On the basis of 16S RNA
sequence analysis this strain possesses a unique lineage and is
most closely related to Streptomyces sp. NRRL S-920, which was
originally isolated from a soil sample of unknown origin. A
more detailed comparison of atpD, rpoB and three other widely
used phylogenetic markers, gyrA (DNA gyrase subunit A), recA
(recombination protein) and trpB (tryptophan biosynthesis)
revealed a 95% shared nucleotide identity between concate-
nated atpD-gyrA-recA-rpoB-trpB and Streptomyces sp. NRRL S-
920, suggesting this strain represents a new species. Given
that it was isolated from Kenyan T. penzigi worker ants, we
suggest the name Streptomyces formicae KY5.Fig. 2 The COSY (bold), selected HMBC (blue arrows), and NOESY
(red double-head arrow) correlations for formicamycin 5. The result-
ing three substructures (Sub1–Sub3) are shown below, and each ring
of the molecule is indicated (rings A–E).S. formicae produces antibacterial and antifungal natural
products
Primary bioassays using B. subtilis, C. albicans and L. prolicans
indicated that S. formicae produces compounds with antibac-
terial and antifungal activity when grown on solid medium.
Fractionation over silica gel showed that these activities could
be separated and high-resolution LCMS analysis suggested the
presence of novel metabolites in the fractions exhibiting
distinct antibacterial and antifungal activities. Very few agents
have been described that are active against the emerging
multidrug resistant fungal pathogen L. prolicans, and the
isolation and characterization of the antifungal metabolites will
be reported elsewhere. Further metabolomics analysis of the
antibacterial fraction suggested a family of structurally related
molecules (congeners) which correlated with the bioactivity
against B. subtilis. In order to isolate suﬃcient material for
detailed structural and biological analysis their production on
MS agar was scaled up (as detailed in ESI†) to yield methanol
extracts containing the target molecules. This included one
experiment where the chemical elicitor sodium butyrate was
added to the MS agar and led to the signicantly enhanced
production of the otherwise trace congener 1 (ESI Fig. S2†).17
Purication of the resulting extracts was achieved using
a combination of normal phase, reversed-phase and size
exclusion chromatography and led to the isolation of 13 indi-
vidual molecules (1–13) in amounts of between 0.3 and 18 mg
(see ESI† for full details). As there are several reports demon-
strating that bromine can substitute for chlorine in microbial
natural products, when provided to growing cultures at appro-
priate levels,18,19 we repeated the production experiment but
grew S. formicae onMS agar containing sodium bromide (2 mM)This journal is © The Royal Society of Chemistry 2017and showed by LCMS that three new brominated congeners
were produced (14–16). This experiment was scaled up and
small amounts (<1 mg) of metabolites 14 and 15 were isolated
while 16 was only detected by MS due to very low levels of
production and the structure is inferred. The molecular
formulae of all compounds 1–16 were measured using high-
resolution MS and their chemical structures determined using
1D and 2D NMR spectroscopy as described below (see Fig. 1
and 2).Structural elucidation of the formicamycins and new
fasamycins
Formicamycin B (5) was isolated rst and its structure deter-
mined. The UV spectrum showed absorptionmaxima at 235 and
286 nm which is characteristic of all formicamycin congeners.
High-resolution ESI-MS indicated a molecular formula of
C29H26Cl2O8 (calculated [M + H]
+ ¼ 573.1077; observed [M + H]+Chem. Sci.
Chemical Science Edge Article
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View Article Online¼ 573.1072; D ¼ 0.96 ppm), suggesting sixteen degrees of
unsaturation. The 13C NMR data was consistent with this and
showed two carbonyl carbons at dC 195.3 and 198.6 ppm, three
methyl carbons at dC 18.3, 29.2 and 34.2 ppm, two methoxy
signals at dC 56.3 and 57.3 ppm, one methylene at dC 30.2 ppm,
and two signals consistent with sp3 quaternary carbons at dC
39.6 and 80.3 ppm. In addition, analysis of HSQC spectra
indicated a sp3 tertiary carbon at dC 49.0 ppm which was hidden
due to the solvent peak of deuterated methanol. It also showed
18 sp2 carbons at dC 98.7–168.0 ppm. The
1H NMR revealed the
presence of ve methyl singlets (dH 1.95, 1.40, 1.64, 3.63 and
3.90 ppm), two methylene proton double doublets (dH 2.77 ppm
(dd, 18.94 Hz and 9.18 Hz) and 3.52 ppm (dd, 18.94 Hz and 6.66
Hz)), one aliphatic proton double doublet (dH 2.56 ppm (dd,
9.18 Hz and 6.66 Hz)), two aromatic proton singlets (dH 6.51 and
6.73 ppm), as well as two aromatic proton doublets (dH
6.14 ppm (d, 2.30 Hz) and 6.45 ppm (d, 2.29 Hz)). Analysis of the
COSY spectrum gave limited data, meaning the majority of
connections were made on the basis of HMBC correlationsFig. 3 Comparison of the experimental and calculated CD spectra of
(10R,19R)-5 (D). The key NOESY correlations for 5 are shown.
Chem. Sci.(Fig. 2). This led to three aromatic substructures consisting of
all 29 carbon atoms, leaving the positions of two chlorine atoms
and four hydroxyl groups unassigned. The signal at dC 80.3 ppm
for C10 is consistent with a sp3 carbon and was assigned as
a tertiary hydroxyl group. The signals for C5, C13, and C15
exhibit canonical phenol chemical shis (dC 150–170 ppm).
Substructures containing rings A and B were connected by a key
HMBC correlation between H24 and C6. Similarly, the resulting
ring-AB substructure is connected to ring-C (see substructure
rings C–E, Fig. 2) by HMBC correlations between H20 and C8,
C21 and C22, as well as the HMBC correlation between H19 and
C21. The two chlorine atoms were therefore assigned to posi-
tions C2 and C22 (dC 113.9 and 121.8 ppm). The assignments
are supported by the vicinal 1H–1H COSY correlations and
NOESY correlations.
With the structure of 5 in hand we were able to readily assign
the remaining structures as described in the ESI.† NOESY
correlations allowed us to link the methoxy at C5 with H4 (e.g. 4,
6, 8–11 and 13). We could also use NOESY correlations to3 (A) and 5 (B), and the lowest energy conformers of (S)-3 (C) and
This journal is © The Royal Society of Chemistry 2017
Table 1 MIC data for 1–15 against B. subtilis, and MRSA and VRE
clinical isolates. Values indicating “Not tested” or with “<” or “>” indicate
issues with compound availability and a decision not to test further
concentrations, i.e. they represent the lowest/highest concentrations
tested
Compound
Minimum Inhibitory Concentration (mM)
B. subtilis MRSA VRE
1 <20 40 40
2 10 10 10
3 5 80 80
4 5 >80 >80
5 10 10 10
6 5 1.25 80
7 10 20 10
Edge Article Chemical Science
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View Article Onlinedistinguish H14 and H16 once one was chlorinated, depending
on their relationship to the gem-dimethyl group (e.g. 7, 8 and 9).
In addition to the formicamycins 4–16, we identied three
related compounds (1–3) which lacked the two chiral centres at
C10 (tertiary hydroxyl group) and C19 (bridgehead proton), and
have an aromatic C-ring structure. These compounds were
signicantly more yellow than 4–16 with distinct UV spectra
(with maxima at 246, 286, 353 and 418 nm) and exhibited
signicantly diﬀerent optical rotations to the formicamycins.
On the basis of these observations we assigned these
compounds as new fasamycin congeners C–E (1–3) respectively.
The fasamycins were rst reported by Brady and co-workers in
2011 15,20 and 1–3 represent new members of this family. We
hypothesise that 1–3 represent biosynthetic precursors of the
formicamycin biosynthetic pathway as discussed below.
To unambiguously assign the pentacyclic skeleton of these
metabolites and conrm their polyketide origin, we performed
a stable isotope labelling experiment. S. formicae was cultivated
on MS agar (2 L) in the presence of [1,2-13C2] sodium acetate.
Aer 7 days incubation the agar was extracted and the most
abundant congener was isolated (compound 4; 5 mg). The
resulting 13C NMR spectra clearly indicated the intact incorpo-
ration of 12 acetate derived units, plus an enriched single
carbon at C24, in a pattern consistent with a polyketide
biosynthetic pathway (see ESI Fig. S3†).8 10 20 10
9 5 20 2.5
10 5 Not tested Not tested
11 10 Not tested Not tested
12 <2.5 <2.5 1.25
13 <20 0.625 1.25
14 <2.5 2.5 5
15 <2.5 1.25 2.5
Fig. 4 Growth inhibition curve and MIC determination for Bacillus
subtilis in the presence of formicamycin 12 (Apr, apramycin; Amp,
ampicillin).Stereochemistry of the fasamycins and formicamycins
Our NMR data alone did not allow congurational analysis of
the two families of compounds to be completed. Although 1–3
lack any chiral centres they exhibit optical activity with
[a]20D values in the range +18 to +27; this optical activity is due
to preferred structures generated by rotation about the chiral
axis of the C6–C7 bond. Additionally, the formicamycins have
chiral centres at C10 and C19 which leads to a shi in aroma-
ticity of ring-C consistent with the distinct UV spectra of these
compounds, and they exhibit much larger magnitude optical
rotations.
To aid in determining their stereochemistry the electronic
circular dichroism (ECD) spectra of fasamycin 3 and for-
micamycin 5 were calculated using time-dependent density
functional theory (TDDFT). First, a systematic conformational
analysis of each isomer was carried out using the MMFFs
molecular mechanics force eld via the Maestro soware
package.21 The conformers obtained within an energetic range
of 3 kcal mol1 of the lowest energy conformer were further
optimized using the PBE1PBE22 exchange-correlation functional
at the def2tzvp23 basis set level and with the SMD solvent
model24 for methanol using the Gaussian09 program package.25
Frequency calculations were then carried out using these same
settings to calculate the relevant percentage of the population of
the conformers. The 30 lowest electronic transitions were then
calculated using TDDFT and the rotational strengths of each
electronic excitation were converted to ECD spectra using
a Gaussian function with a half-bandwidth of 0.248 eV. The
overall ECD spectra were then generated according to the
Boltzmann weighting of each conformer.This journal is © The Royal Society of Chemistry 2017For the fasamycins, rotation about the C6–C7 axis means ring-
A can be drawn with either the ortho hydroxyl or methyl group
pointing forwards which correspond to the S- or R-congurations
respectively. Comparison of the experimentally obtained ECD
spectra for 3 to those calculated gives excellent agreement with
that calculated for the S-conguration (Fig. 3A and ESI Fig. S3†)
strongly suggesting this represents the preferred conformation.
For 5 we rst compared the predicted structures for the lowest
energy conformations of both the (10RS,19RS) and (10SR,19RS)Chem. Sci.
Chemical Science Edge Article
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View Article Onlinediastereoisomeric pairs to data from NOSEY experiments. As
observed in ESI Fig. S6† the (10SR,19RS) isomers with a trans
relationship of the C10 and C19 substituents adopt an extended
conformation of the four fused rings B–E. In contrast the cis
(10RS,19RS) isomers are predicted to adopt a twisted L-shaped
conformation (Fig. 3D). From this comparison the methine
proton at C19 becomes diagnostic as the (10RS,19RS) isomers
should show strong correlations to both methyl groups attached
to C18 (methyl-26/27), whereas for the (10SR,19RS) isomers it
should only give a correlation to methyl-27. Analysis of the
NOESY data shows strong correlations for both methyl groups
(26/27), and the remaining correlation data are also consistent
with that expected for the (10RS,19RS) isomers (see Fig. 2 and
3D). We then acquired additional NMR datasets for 5 in non-
protic solvent (d6-DMSO/d3-acetonitrile) and were able to locate
the signal for the exchangeable hydroxyl proton at C10. Analysis
of the NOESY spectrum showed clear correlations for this proton
to the methine proton at C19 and methyl-27 which is compatible
with the cis (10RS,19RS) isomers, but not the trans (10SR,19RS)
isomers. NOESY data for the remaining formicamycin congeners
was also consistent with the cis (10RS,19RS) conguration in each
case. On this basis we were able to rule out the trans (10SR,19RS)
isomers and proceeded to analyse the calculated andFig. 5 Organization of the formicamycin (for) BGC and annotation of put
synthase; MFS ¼ major facilitator superfamily.
Chem. Sci.experimentally determined ECD spectra for the cis (10R,19R) and
(10S,19S) enantiomers of 5 (Fig. 3B and ESI Fig. S4 and S5†).
These data strongly suggested that the (10R,19R) stereochemistry
was correct. Therefore, using combined NOESY NMR and ECD
data we assign the (10R,19R) stereochemistry to the for-
micamycins. However, we are unable to make a denitive state-
ment regarding the chiral C6–C7 axis for the formicamycins.
Formicamycins exhibit potent activity against Gram-positive
bacteria including drug resistant clinical isolates
To examine their structure activity relationship (SAR) we
examined the growth of B. subtilis in liquid media supple-
mented with 0.01–100 mM of 1–15. The MIC for each compound
against B. subtilis is shown in Table 1 and the growth curve for
one of the most potent (12) is shown in Fig. 4. All compounds
eﬀectively inhibit the growth of B. subtilis with an increase in
potency observed for compounds containing an increasing
number of chlorine atoms. Interestingly, brominated
compounds appear to be slightly more potent than the equiv-
alent chlorinated formicamycins. A shi from the fasamycin to
formicamycin congeners also correlates with an increase in
activity although it is unclear whether the ability to poly-
halogenate this scaﬀold is the overriding factor.ative gene products. ACC ¼ acetyl-CoA carboxylase; PKS ¼ polyketide
This journal is © The Royal Society of Chemistry 2017
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View Article OnlineTo test whether 1–15 can inhibit drug-resistant Gram-
positive bacteria we tested them against clinical isolates of
MRSA and vancomycin-resistant Enterococcus faecium (VRE) (see
ESI†) and found that the formicamycins are eﬀective inhibitors
of these organisms (Table 1). During the course of these
experiments we observed that our test strains did not acquire
spontaneous resistance when cultured on agar containing for-
micamycins. To test this further, we grew MRSA for four
generations in the presence of no compound (control) and half
MICs of compounds 6, 13 and 15. We then repeated the MIC
tests and found no diﬀerence between the MRSA strains sug-
gesting no resistance had arisen to formicamycins. We repeated
the experiment but this time grew the strains for 20 generations
and again found no increase in the MICs for these compounds,
suggesting they exhibit a high barrier for the selection of
resistant mutants, at least under the conditions tested here.Fig. 6 Deletion of BGC30 abolishes formicamycin biosynthesis, and
forV encodes a halogenase gene. HPLC traces (250 nm) showing: (A)
isolated 1–13 (mixed); (B) S. formicae wild-type; (C) S. formicae Dfor;
(D) S. formicae Dfor/pESAC13-215-G; (E) S. formicae DforV; (F) S.
formicae DforV/forV.Identication of the formicamycin BGC
Based on their structures we predicted that biosynthesis of the
formicamycins would be encoded by a BGC containing type 2
polyketide synthase (PKS) genes. Analysis of the S. formicae
genome using antiSMASH 3.0 13 identied only one type 2 PKS
gene cluster (BGC30) which we designate for (Fig. 5; Table S2;†
accession number: KX859301). We used the CRISPR/Cas9 vector
pCRISPomyces-2 26 to delete the entire BGC30 and surrounding
genes in order to generate the unmarked deletion strain S. formicae
Dfor; deletion of the BGC was conrmed by PCR amplication and
sequencing (see ESI†). The wild-type strain and four independently
generated S. formicae Dfor mutants were then grown in parallel
under formicamycin producing conditions and subsequent
LCMS(UV) analysis of extracts conrmed that fasamycin/
formicamycins were not produced by the mutant strains (Fig. 6B
and C). To ensure that loss of fasamycin/formicamycin biosyn-
thesis was due to genome editing, and not other mutational
events, we utilized a PAC (P1-derived articial chromosome) library
of the S. formicae genomic DNA which was custom made in
pESAC13 by BioS&T Co. (Montreal, Canada). This was screened
with three primer pairs (Table S1†), amplifying fragments either
side and in the centre of BGC30. A single clone carrying the entire
BGC30 (pESAC13-215-G) was introduced into one of the fasamycin/
formicamycin-decient mutants using tri-parental mating.27
LCMS(UV) analysis of the complemented strain alongside wild-
type and mutant strains conrmed that fasamycin/formicamycin
biosynthesis had been restored (Fig. 6D), and we conclude that
BGC30 encodes the biosynthesis of compounds 1–13 in S. formicae.ForV is a halogenase required for formicamycin biosynthesis
Despite the identication of formicamycin congeners contain-
ing up to four halogen atoms we could identify only a single
gene (forV) in BGC30 likely to encode a halogenase. Further-
more, analysis of the S. formicae genome identied only two
further genes encoding potential halogenase enzymes that were
associated with other BGCs (data not shown). ForV is a putative
Flavin dependent halogenase, a family of enzymes which have
been widely studied as catalysts involved in natural productsThis journal is © The Royal Society of Chemistry 2017biosynthesis,28 and a homologue of forV is present in the fasa-
mycin BGC.15,20
To investigate its biosynthetic role we deleted the forV coding
sequence using CRISPR-Cas9 methodology. Four independently
isolatedmutants were veried by PCR and sequencing, and extracts
of the mutants grown on MS agar were analysed by LCMS(UV)
(Fig. 6E). This showed accumulation of the non-halogenated fasa-
mycin C (1) plus a newmolecule with the samemolecular formulae
and UV spectrum indicating that it is a structural isomer of 1
(presumably bearing an O-methyl group at either C5 or C23 rather
than at C3). The production levels of 1 by this mutant is approx.
188-fold that observed for the wild-type strain. Notably, no for-
micamycins could be observed in this extract. These data strongly
suggest that ForV is responsible for the introduction of up to four
halogen atoms. Genetic (in trans) complementation with the forV
gene under the control of the native promoter re-established
production of the halogenated compounds 2 and 3 and the for-
micamycins (Fig. 6F) indicating there was no polar eﬀect or
unanticipated genetic mutation introduced by the gene editing.Biosynthesis of the formicamycins
Prior to this investigation no experiments regarding the
biosynthesis of the fasamycins or formicamycins had beenChem. Sci.
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View Article Onlinereported, although a pathway was proposed for the former
based on sequencing of the fasamycin BGC and bioinformatics
analysis.15 Based on the isotope feeding experiments, compar-
ative bioinformatics and mutational analysis described above
we are able to propose a biosynthetic pathway and assign
putative functions to the BGC30 gene products (Fig. 5 and 7).
Bacterial type 2 PKSs are characterized by a minimal set of gene
products composed of the heterodimeric b-ketosynthase (KS)
pair KSa/KSb and an acyl carrier protein which are critical in
determining polyketide chain length and the overall topology of
the ring system to be made. We propose that ForABC comprise
the minimal PKS and produce a tridecaketide intermediate 17
which, through the action of the putative additional tailoring
enzymes including PKS cyclase/dehydratases (ForD, ForL,
ForR), a hydrolase (ForN) and a decarboxylase (ForQ), is con-
verted into 18 and then 19.
All of 1–16 contain two methyl groups at C18 which, in
conjunction with biosynthetic studies on the related pentan-
gular polyketide benastatin,29 suggests that the rst post-PKS
step will involve installation of the gem-dimethyl group at
C18. Three putative methyltransferases are encoded in BGC30
(ForM, ForT, and ForW), and ForT has the highest sequenceFig. 7 Proposed biosynthetic pathway for the fasamycins/formicamycin
units incorporated into the polyketide backbone. cMT, C-methyltransfer
Chem. Sci.shared identity with BenF (66%/49%; CAM58795.1) which
catalyses the gem-dimethylation step during benastatin
biosynthesis and is likely to catalyse the equivalent reaction
during fasamycin/formicamycin biosynthesis; this gene is also
present in the fasamycin BGC.15 Our inability to identify and
isolate the putative intermediate 19, or indeed any congeners
lacking the gem-dimethyl moiety, leaves open the possibility
that this molecule may not exist as an enzyme free intermediate
and that ForT might actually act upon an ACP-bound interme-
diate which is then released and decarboxylated. Additionally,
we did not isolate any congeners lacking a methoxy-group at C3
which suggests that O-methylation at this position occurs next
and will be catalysed by one of the remaining methyl-
transferases ForM or ForW to yield 1.
The accumulation of only 1 and a new isomer in the forV
deletion mutant suggests that chlorination is the next step of
the biosynthetic pathway and that it is essential to enable
further post-PKS steps to occur in order to produce the for-
micamycins. This is consistent with the low levels of 1–3
observed from the wild-type organism, and analysis of the
chlorination patterns for 2–13 suggests that chlorination at C2
or C22 is essential, with C22 likely being preferred to yield 2.s. Bold bonds in 17 indicate the positions of [1,2-13C2] sodium acetate
ase; oMT, O-methyltransferase.
This journal is © The Royal Society of Chemistry 2017
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View Article OnlineIntroduction of the tertiary hydroxyl group at C10 and
modication of ring-C probably occurs next in the biosynthetic
sequence. Moreover, as we only identied formicamycins con-
taining both of these changes we propose that the trans-
formations are linked, and may be catalyzed by the combined
actions of the avin dependent monooxygenase ForX and avin
dependent oxidoreductase ForY to yield 20. A second O-meth-
ylation at C23 most likely occurs next (to give 21) as all for-
micamycins contain this change. It is currently unclear when
the nal O-methylation at C5 occurs.
Finally, the most abundant formicamycin congeners contain
either three or four chlorine atoms located on three diﬀerent
rings, and the minor congeners contain mostly two or three
chlorine atoms distributed around the various locations; no
fasamycins have a chlorine atom on ring E. These observations
are consistent with the idea that ForV is a promiscuous enzyme
capable of catalysing up to four halogenation reactions on
a single molecule, but that there is a preferred, but not absolute,
ordering to these modications.
Comparison to the fasamycin BGC15 fails to identify homo-
logues of certain genes present in BGC30 that we propose may
be involved in formicamycin biosynthesis. In contrast others
are present in both BGCs that we suggest may be responsible
for some of the structural diﬀerences observed. Plausible
reasons for these diﬀerences include diﬀerential expression, or
a lack of expression in one species, and the involvement of
genes that were not captured on the expression cosmid used for
production of the fasamycins.15 To address these questions
a detailed study of formicamycin biosynthesis is underway in
our labs.
Conclusions
Most of the antibiotics in clinical use are derived from the
natural products of soil microbes, most notably species of
Streptomyces bacteria that were discovered more than 50 years
ago. Here we highlight how searching under-explored environ-
ments combined with new advances in genome sequencing and
editing enables the discovery of new species making natural
products with potent anti-infective activity that could bypass
resistance and form the basis of new anti-infective therapies.
Specically, we identied a new species, Streptomyces formicae,
from the African plant-ant Tetraponera penzigi, and show that it
makes a family of rare pentangular polyketide antibiotics. These
new molecules, which we call the formicamycins, inhibit the
growth of the clinically relevant pathogens MRSA and VRE. The
formicamycins are more potent than the previously reported
and structurally related fasamycins.15,20 Spontaneous resistance
to fasamycins was used to identify their molecular target but our
data suggest that the formicamycins have a higher barrier for
the selection of resistant mutants, at least for MRSA, under the
conditions examined here. The reason for increased potency of
the poly-halogenated congeners may simply be due to increased
lipophilicity and an enhanced ability to cross the bacterial cell
membrane. Moreover, docking studies reported during the
previous work on fasamycins mode of action suggest that the
chloro-gem-dimethyl-anthracenone substructure represents theThis journal is © The Royal Society of Chemistry 2017key pharmacophore.20 This region comprises the key structural
diﬀerences between the two chemotypes as exemplied by the
three dimensional structure presented in Fig. 3 and it is
currently unclear whether their molecular target and mode of
action may diﬀer. This will be addressed in future studies.
Intriguingly, bioinformatics analysis shows that the for-
micamycin BGC is closely related to an unassigned BGC present
in the genome of Streptomyces kanamyceticus (Genbank ID
LIQU00000000.1). Further, an approx. 188 kbp region of the S.
formicae genome, which encompasses BGC30, is syntenic with
the S. kanamyceticus genome (extending approx. 64 kbp
upstream and at least 95 kbp downstream, which is as far as the
contig LIQU01000034 extends) and we suggest there has been
a horizontal gene transfer event. Further bioinformatics anal-
ysis and consideration of the biosynthetic pathway leads us to
propose that forQ and forCC represent the boundaries of BGC30
(Fig. 4). Additionally, the region of sequence encoding forX to
forAA, which is not present on the S. kanamyceticus genome,
comprises gene sequences with closest homologues in Actino-
madura species, and appears to have been inserted into the S.
kanamyceticus syntenic sequence. This suggests the for-
micamycin BGC may have its origin in multiple horizontal
transfer events. Further work, both to understand the origins of
the formicamycin BGC, and to delineate their biosynthesis, are
underway in our laboratories. We anticipate this data will aid in
the application of biosynthetic medicinal chemistry methods to
produce further improved molecules with potential application
as antibacterial agents.Materials and methods
For details regarding experimental procedures, spectroscopic
and chromatographic data, microbiology andmolecular biology
procedures, genome sequencing and the proposed function of
gene products, see the ESI.†Acknowledgements
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